Maze Therapeutics, Inc. (MAZE) Earnings History
Net Loss4 years of earnings data (2022–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Maze Therapeutics, Inc. (MAZE) Earnings Overview
As of June 12, 2026, Maze Therapeutics, Inc. (MAZE) reported trailing twelve-month net income of -$123M, reflecting -4020.3% year-over-year growth. The company earned $-2.27 per diluted share over the past four quarters.
Looking at the long-term picture, MAZE's historical earnings data spans multiple years. The company achieved its highest annual net income of $52M in fiscal 2024.
Maze Therapeutics, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including RARE (-$609M net income, -85.4% margin), FOLD (-$27M net income, -4.3% margin), ACMR ($91M net income, 10.4% margin), MAZE has comparable earnings metrics. Compare MAZE vs RARE →
MAZE Earnings vs Peers
Earnings metrics vs comparable public companies
MAZE Historical Earnings Data (2022–2025)
4 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$131M | -351.0% | -$143M | $-3.05 | - | - |
| 2024 | $52M | +152.0% | $58M | $0.08 | 31.2% | 34.4% |
| 2023 | -$100M | +12.6% | -$99M | $-2.29 | - | - |
| 2022 | -$115M | - | -$111M | $-2.63 | - | - |
Download Data
Export MAZE earnings history in CSV or JSON format
Free sign-in required to download data
What if you invested $1,000 in MAZE back in 2022?
Total return with dividends reinvested · 4+ years of data
Calculate ReturnsHow much would $100/month in MAZE be worth today?
Dollar cost averaging vs lump sum · see how regular investing compounds over time
Run the NumbersIs MAZE Undervalued Right Now?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationMAZE vs LLY — which is the better buy?
Side-by-side revenue, margins, P/E and 10-year returns vs Eli Lilly and Company.
Compare NowMAZE — Frequently Asked Questions
Quick answers to the most common questions about buying MAZE stock.
What is MAZE earnings per share (EPS)?
MAZE trailing twelve-month (TTM) diluted EPS is $-2.27, reflecting -4020.3% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2022 to 2025 is available in the table on this page.
What is Maze Therapeutics, Inc.'s net income?
Maze Therapeutics, Inc. (MAZE) trailing twelve-month net income is $-123M as of 2025. Earnings declined -4020.3% year-over-year.
Is MAZE profitable?
MAZE is not currently profitable on a TTM basis, reporting a net loss of $-123M. Net margin is N/A. Investors should monitor for a return to profitability.
What is MAZE's earnings growth rate?
MAZE compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2022 to 2025.
What are MAZE's profit margins?
Maze Therapeutics, Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -47.5%.
Is MAZE growing earnings?
MAZE earnings are declining — EPS fell -4020.3% year-over-year. TTM net income dropped to $-123M. This contrasts with the 5-year CAGR of N/A.
What was MAZE's best earnings year?
Maze Therapeutics, Inc.'s highest annual net income on record is $52M, achieved in fiscal year 2024. Earnings history on this page spans 2022 to 2025 and includes all annual and quarterly figures.
What were MAZE's earnings last quarter?
MAZE's most recent reported quarter was Q1 2026. Net income was $-24M with diluted EPS of $-0.45. For a full breakdown of all quarters, see the quarterly earnings table on this page.